Remove 2029 Remove Compounding Remove Dosage Remove FDA
article thumbnail

Novo Nordisk blockbuster Ozempic boasts 23% sales surge in 2023

Pharmaceutical Technology

Originally granted approval in its largest market, the US, in 2017, Ozempic has subsequently obtained approval for three distinct dosages, 0.5mg, 1.0mg, and 2.0mg, for the treatment of type 2 diabetes. It is forecast that Ozempic will sustain its sales growth over the next five years, with an expected annual sales figure of $17bn in 2029.

Dosage 52
article thumbnail

Top Performing Drug of 2021 - Trulicity (February Edition)

PharmaShots

Active Ingredient: dulaglutide Dosage Forms & Strengths: Injection: 0.75 Some of its FDA-approved competitors include: Patents7 Eli Lilly carries big expectations from Trulicity to boost its revenue. In the US, Trulicity is protected by a compound patent (2027) and by biologics data protection (2026). mL, 3 mg/0.5